Researchers successfully used a noninvasive broadband optical spectroscopy (BOS) device to detect necrotizing enterocolitis (NEC) early in premature infants.
Key Details
- 1BOS is a handheld device that measures reflected infrared light from the intestines to detect early NEC.
- 2The technology distinguishes NEC from healthy tissue within two minutes at the bedside.
- 3First-in-human study tested BOS on 96 premature infants younger than 36 weeks gestation.
- 4BOS produced safe, feasible, and detectable signal changes in infants with NEC.
- 5BOS may identify NEC before it appears on x-ray; prior x-ray is the current standard diagnostic tool.
Why It Matters
BOS could allow bedside, early, radiation-free detection of NEC—a life-threatening disease—enabling earlier treatment and potentially improving outcomes in neonates. The move toward new optical imaging modalities may supplement or even precede conventional radiology tools like x-ray in this clinical scenario.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.